Yulang Xu

49PUBLICATIONS
18CO-AUTHORS
Molecular targetsEpidemiology not elsewhere classifiedHaematological tumoursMedical virologyPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (49)

|Sep 17, 2026
Precision Medicine for Somatic Mutation-Driven Vascular Anomalies.

|Aug 27, 2026
High Responsiveness of Head and Neck Kaposiform Hemangioendothelioma Without Kasabach-Merritt Phenomenon to Sirolimus Monotherapy.

|Jul 14, 2026
Propranolol monotherapy versus propranolol plus prednisone for diffuse infantile hepatic haemangioma: a randomized clinical trial.

|Mar 16, 2026
Spontaneous Regression of Kaposiform Hemangioendothelioma Without Kasabach-Merritt Phenomenon.

Yulang Xu, Jie Liu, Jiangyuan Zhou

|Dec 01, 2025
Hepatotoxicity Mechanisms of Sirolimus and Everolimus Unveiled Through Metabolomics and Transcriptomics Analysis.

Zixin Zhang, Yingying Tang, Rongjing Xing

|Oct 22, 2025
An Examination of Sirolimus's Role in Endothelial Cells of Kaposiform Haemangioendothelioma.

Yanan Li, Chuan Wang, Meng Kong

Pageof 9

Frequent Collaborators

6 joint publications

Linyu Yang

3 joint publications

Xuepeng Zhang

3 joint publications

Siyuan Chen

3 joint publications

Yulang Xu